1. Home
  2. THAR vs SPRC Comparison

THAR vs SPRC Comparison

Compare THAR & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THAR
  • SPRC
  • Stock Information
  • Founded
  • THAR 2017
  • SPRC 2004
  • Country
  • THAR United States
  • SPRC Israel
  • Employees
  • THAR N/A
  • SPRC N/A
  • Industry
  • THAR Biotechnology: Pharmaceutical Preparations
  • SPRC Biotechnology: Pharmaceutical Preparations
  • Sector
  • THAR Health Care
  • SPRC Health Care
  • Exchange
  • THAR Nasdaq
  • SPRC Nasdaq
  • Market Cap
  • THAR 4.0M
  • SPRC 3.5M
  • IPO Year
  • THAR 2022
  • SPRC N/A
  • Fundamental
  • Price
  • THAR $1.25
  • SPRC $0.30
  • Analyst Decision
  • THAR Strong Buy
  • SPRC
  • Analyst Count
  • THAR 1
  • SPRC 0
  • Target Price
  • THAR $17.00
  • SPRC N/A
  • AVG Volume (30 Days)
  • THAR 135.2K
  • SPRC 6.1M
  • Earning Date
  • THAR 05-08-2025
  • SPRC 02-15-2025
  • Dividend Yield
  • THAR N/A
  • SPRC N/A
  • EPS Growth
  • THAR N/A
  • SPRC N/A
  • EPS
  • THAR N/A
  • SPRC N/A
  • Revenue
  • THAR N/A
  • SPRC $1,747,000.00
  • Revenue This Year
  • THAR N/A
  • SPRC N/A
  • Revenue Next Year
  • THAR N/A
  • SPRC N/A
  • P/E Ratio
  • THAR N/A
  • SPRC N/A
  • Revenue Growth
  • THAR N/A
  • SPRC N/A
  • 52 Week Low
  • THAR $1.20
  • SPRC $0.20
  • 52 Week High
  • THAR $7.13
  • SPRC $2.10
  • Technical
  • Relative Strength Index (RSI)
  • THAR 32.14
  • SPRC 36.90
  • Support Level
  • THAR $1.20
  • SPRC $0.30
  • Resistance Level
  • THAR $1.47
  • SPRC $0.32
  • Average True Range (ATR)
  • THAR 0.15
  • SPRC 0.03
  • MACD
  • THAR -0.01
  • SPRC 0.00
  • Stochastic Oscillator
  • THAR 2.04
  • SPRC 15.17

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

About SPRC SciSparc Ltd.

SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Share on Social Networks: